Additionally, Fernández' et al showed that Bcl-xL expression in breast cancer cells could increase metastatic activity and this advantage could be created by inducing resistance to apoptosis against cytokines, increasing cell survival in circulation, and enhancing anchorage-independent growth [22]. Here, BCL2L1 is linked to breast carcinoma.